Irinotecan liposome

DRUG16 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd., ImmunityBio, Inc., The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Shanghai Zhongshan Hospital, Fudan University

Conditions

Advanced Esophageal Squamous Cell CancerAdvanced Esophageal Squamous Cell CarcinomaAdvanced Solid TumorsBiliary Tract CarcinomaColorectal CancerExtensive-stage Small-cell Lung CancerMetastatic Colorectal CancerPancreatic Cancer

Phase 1

A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors

CompletedNCT05086822

Jiangsu HengRui Medicine Co., Ltd.Advanced Solid Tumors

Start: 2014-09-09End: 2017-08-28Updated: 2021-10-21

Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

RecruitingNCT06225622

Shanghai Zhongshan HospitalMetastatic Colorectal Cancer

Start: 2024-03-11End: 2026-05-01Target: 78Updated: 2024-03-19

Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer

Not yet recruitingNCT06341309

West China HospitalMetastatic Colorectal Cancer

Start: 2024-08-09End: 2026-08-01Target: 20Updated: 2024-08-09

Phase 2

SHR-1316 in Combination With Chemotherapy in Patients With Esophageal Squamous Cell Cancer

Jiangsu HengRui Medicine Co., Ltd.Advanced Esophageal Squamous Cell Cancer

Start: 2018-11-30End: 2020-10-31Target: 30Updated: 2018-11-06

Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Active, not recruitingNCT04390399

ImmunityBio, Inc.Pancreatic Cancer

Start: 2020-07-21End: 2026-05-31Target: 328Updated: 2025-12-15

Radiotherapy Combined With Irinotecan and Apatinib Followed by PD-1 Antibody and Apatinib for Advanced Solid Tumors

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSolid Tumor

Start: 2020-09-30End: 2023-05-31Target: 30Updated: 2020-09-30

Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer

RecruitingNCT06341296

West China HospitalMetastatic Colorectal Cancer

Start: 2024-06-30End: 2026-12-31Target: 86Updated: 2024-08-12

Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer

RecruitingNCT06475326

Fudan UniversityPancreatic Cancer

Start: 2024-06-05End: 2025-12-31Target: 87Updated: 2024-08-09

A Study to Investigate the Efficacy and Safety of Ivonescimab Combined With Irinotecan Liposome as Second-line Regimen for ES-SCLC

Not yet recruitingNCT06478043

Zhejiang Cancer HospitalExtensive-stage Small-cell Lung Cancer

Start: 2024-09-01End: 2027-09-01Target: 54Updated: 2024-07-08

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

RecruitingNCT06512428

Shanghai Runshi Pharmaceutical Technology Co., LtdAdvanced Esophageal Squamous Cell Carcinoma

Start: 2024-03-15End: 2026-01-30Target: 138Updated: 2024-07-22

Adebelimab Combined With Irinotecan Liposomal Injection, Oxaliplatin, Fluorouracil and Calcium Folinate Are Used in the First-line Treatment of Pancreatic Cancer Liver Metastasis Efficacy and Safety

RecruitingNCT06531278

Jiang LongPancreatic Cancer Metastatic to Liver

Start: 2024-07-16End: 2026-12-31Target: 40Updated: 2024-07-31

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

RecruitingNCT06657690

Sun Yat-sen UniversityRecurrent or Metastatic Nasopharyngeal Carcinoma

Start: 2024-11-01End: 2027-10-31Target: 56Updated: 2025-01-10

Irinotecan Liposomes +5-FU/LV Versus Capecitabine in Patients of Recurrence After Resection of Resectable BTC

Not yet recruitingNCT06699459

Sir Run Run Shaw HospitalBiliary Tract Carcinoma

Start: 2024-11-14End: 2026-11-15Target: 76Updated: 2024-11-21

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

RecruitingNCT07070479

Ming-Yuan ChenRecurrent or Metastatic Nasopharyngeal Carcinoma

Start: 2025-06-24End: 2028-01-30Target: 208Updated: 2025-09-18

Unknown Phase

Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

RecruitingNCT06258642

Fudan UniversitySmall Cell Lung Cancer Recurrent

Start: 2024-04-17End: 2026-12-31Target: 39Updated: 2025-08-20

Real-world Study to Evaluate the Efficacy and Safety of Liposome Irinotecan

RecruitingNCT06443307

Peking UniversityColorectal Cancer, Solid Tumor

Start: 2024-07-15End: 2026-08-01Target: 933Updated: 2024-06-05

Related Papers

Irinotecan liposome combined with anlotinib as second-line treatment in patients with small cell lung cancer (SCLC).

Journal of Clinical Oncology2025-05-281 citations

Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3 <sup>rd</sup> line or greater metastatic pancreatic cancer.

Journal of Clinical Oncology2025-05-28

Phase II study of irinotecan liposome combined with 5-FU/LV + bevacizumab as first-line therapy in metastatic colorectal cancer: An early analysis from the study.

Journal of Clinical Oncology2025-05-28

Abstract 5255: Systemic immunosuppression in pancreatic cancer

Cancer Research2025-04-21

Multicenter, single-arm, phase II study (CAP) of radiotherapy plus liposomal irinotecan followed by camrelizumab and anti-angiogenic treatment in advanced solid tumors

Frontiers in Immunology2023-03-285 citations

Phase 2 Quilt 88 trial of DAMP inducers combined with IL15 superagonist, N-803, and anti–PD-L1 NK cell therapy more than doubles historical overall survival in patients with third- to sixth-line advanced pancreatic cancer.

Journal of Clinical Oncology2022-06-015 citations

A phase II study to evaluate the safety and efficacy of radiotherapy combined with irinotecan liposome followed by camrelizumab and apatinib for advanced solid tumors that failed standard treatments.

Journal of Clinical Oncology2022-06-013 citations

Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemo-radiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1- NK cell therapy.

Journal of Clinical Oncology2022-01-195 citations

Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

Journal of Clinical Oncology2021-05-203 citations